Compare APEI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APEI | NBTX |
|---|---|---|
| Founded | 1991 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2007 | 2018 |
| Metric | APEI | NBTX |
|---|---|---|
| Price | $53.52 | $28.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $52.14 | $26.00 |
| AVG Volume (30 Days) | ★ 434.3K | 45.0K |
| Earning Date | 03-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 147.27 | N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $198,174,000.00 | N/A |
| Revenue This Year | $8.37 | N/A |
| Revenue Next Year | $7.17 | $11.73 |
| P/E Ratio | $40.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.75 | $2.99 |
| 52 Week High | $58.69 | $41.89 |
| Indicator | APEI | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.09 | 47.16 |
| Support Level | $40.65 | $20.11 |
| Resistance Level | $58.69 | $30.23 |
| Average True Range (ATR) | 2.88 | 2.61 |
| MACD | 0.67 | -0.76 |
| Stochastic Oscillator | 66.81 | 1.93 |
American Public Education Inc provides online and campus based postsecondary education including various undergraduate and graduate degree programs. The fields of study include business administration, health science, technology, criminal justice, education, liberal arts, national security, military studies, intelligence, and homeland security. There are three reporting segments: the American Public University segment which is the key revenue generator, provides online postsecondary education as a distance-learning, graduate-level institution for military officers seeking a degree in military studies; the Rasmussen University Segment and the Hondros College of Nursing segment. The revenue is generated from net course registrations and enrollment, tuition rate, net tuition, and other fees.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.